...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transfusion and apheresis science: official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis >The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma
【24h】

The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma

机译：多发性骨髓瘤大剂量化疗和自体CD34+回输后CD34+剂量与血小板恢复的关系

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for multiple myeloma (MM), yet the impact of transplanted CD34+ cell dose remains unresolved, especially in patients over the age of 65 years. Data was collected from 207 consecutive ASCT patients to determine the relationship between CD34+ infusion count and short-term and long-term platelet recovery. For MM patients under the age of 65 years ( n =155), CD34+ dosage correlates with time to platelet engraftment ( p p =0.003), but not with long-term platelet counts at 180 or 360 days from the CD34+ reinfusion. For MM patients aged 65 years or older ( n =46), CD34+ dosage did not correlate with time to platelet engraftment, but did correlate with both short-term and long-term platelet counts at 30 ( p p =0.021), and 360 days ( p =0.005). Exploratory regression analysis was done to explore platelet stability following the current minimum CD34+ dosage reinfusion. For MM patients under the age of 65 years, the minimum standard CD34+ dosage of 2×10 6 cells/kg was sufficient for a timing to platelet engraftment of 9 /L at 30 days. Alternatively, for MM patients aged 65 years or older, the CD34+ dosage of 2×10 6 cells/kg was insufficient for platelet counts ≥150×10 9 /L at 30 and only marginally attainable at 360 days suggesting that in elderly MM patients a higher CD34+ dosage may be required for platelet recovery and possibly long-term platelet stability. >
机译：摘要 自体造血干细胞移植（ASCT）是治疗多发性骨髓瘤（MM）的成熟方法，但移植CD34+细胞剂量的影响仍未解决，尤其是65岁以上的患者。从 207 例连续 ASCT 患者中收集数据，以确定 CD34+ 输注计数与短期和长期血小板恢复之间的关系。对于 65 岁以下的 MM 患者 （n =155），CD34+ 剂量与血小板植入时间相关 （ p p =0.003），但与 CD34+ 回输后 180 或 360 天的长期血小板计数无关。对于 65 岁或以上的 MM 患者 （n = 46），CD34+ 剂量与血小板植入时间无关，但与 30 天 （p p =0.021） 和 360 天 （p =0.005） 的短期和长期血小板计数相关。进行探索性回归分析以探索当前最低剂量 CD34+ 回输后的血小板稳定性。对于 65 岁以下的 MM 患者，最低标准 CD34+ 剂量为 2×10 6 个细胞/kg，足以在 30 天时进行 9 个/L的血小板植入。或者，对于 65 岁或以上的 MM 患者，2×10 6 个细胞/kg 的 CD34+ 剂量不足以满足 30 时血小板计数≥150×10 9 /L，并且在 360 天时只能勉强达到，这表明在老年 MM 患者中，可能需要更高的 CD34+ 剂量才能恢复血小板恢复并可能长期血小板稳定性。]]>

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号